Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2025 08:00 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for...
June 13, 2025 08:00 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics to Participate in the 2025 BIO International Conference

PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage,...
April 09, 2025 08:00 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage,...
February 25, 2025 08:00 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing...
February 13, 2025 08:00 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of...
February 10, 2025 08:05 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential...
February 10, 2025 08:01 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 ...
January 07, 2025 08:00 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Nasdaq: ACST) (Grace Therapeutics or the Company), a late-stage, biopharma...
December 04, 2024 08:00 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference

PRINCETON, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Nasdaq: ACST) (Grace Therapeutics or the Company), a late-stage, biopharma...
November 13, 2024 08:00 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update

STRIVE-ON Data Readout Expected First Calendar Quarter 2025; NDA Submission on Track for 1H Calendar 2025 Completed Corporate Re-Branding, Connecting Company to Rich Scientific Legacy of Grace...